Hepatotoxicity related to methotrexate

Drug-Induced Liver Disease

Volumn , Issue , 2013, Pages 593-604

  Aithal, Guruprasad P ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Adverse reaction; Biomarker; Chronic liver disease; Cirrhosis; Drug induced liver injury; Fatty liver; Fibrosis; Hepatotoxicity; Methotrexate; Steatosis

Indexed keywords

EID: 84882591232     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387817-5.00032-7     Document Type: Chapter

References (89)

1. Gubner R. Effect of aminopterin on epithelial tissues. AMA Arch Derm Syphilol 1951, 64:688-699.
2. Zachariae H. Methotrexate side-effects. Br J Dermatol 1990, 122(Suppl 36):127-133.
3. Collins P., Rogers S. The efficacy of methotrexate in psoriasis-a review of 40 cases. Clin Exp Dermatol 1992, 17:257-260.
4. Van Dooren-Greebe R.J., Kuijpers A.L., Mulder J., De Boo T., Van de Kerkhof P.C. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994, 130:204-210.
5. Kalb R.E., Strober B., Weinstein G., Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009, 60:824-837.
6. Collin B., Srinathan S.K., Finch T.M. Methotrexate: prescribing and monitoring practices among the consultant membership of the British Association of Dermatologists. Br J Dermatol 2008, 158:793-800.
7. Berkowitz R.S., Goldstein D.P., Bernstein M.R. Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986, 23:111-118.
8. Banerjee A.K., Lakhani S., Vincent M., Selby P. Dose-dependent acute hepatitis associated with administration of high dose methotrexate. Hum Toxicol 1988, 7:561-562.
9. Schmiegelow K., Pulczynska M. Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia. Br J Cancer 1990, 61:767-772.
10. Hakim N.S., Kobienia B., Benedetti E., Bloomer J., Payne W.D. Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis. Int Surg 1998, 83:224-225.
11. Aithal G.P., Watkins P.B., Andrade R.J., Larrey D., Molokhia M., Takikawa H., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011, 89:806-815.
12. Kishi S., Cheng C., French D., Pei D., Das S., Cook E.H., et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007, 109:4151-4157.
13. O'Rourke R.A., Eckert G.E. Methotrexate-induced hepatic injury in an adult. A case report. Arch Intern Med 1964, 113:191-194.
14. Bjorkman D.J., Hammond E.H., Lee R.G., Clegg D.O., Tolman K.G. Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1988, 31:1465-1472.
15. Ros S., Juanola X., Condom E., Cañas C., Riera J., Guardiola J., et al. Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Scand J Rheumatol 2002, 31:330-336.
16. Roenigk H.H., Auerbach R., Maibach H., Weinstein G., Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998, 38:478-485.
17. Aithal G.P., Haugk B., Das S., Card T., Burt A.D., Record C.O. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?. Aliment Pharmacol Ther 2004, 19:391-399.
18. Thomas J.A., Aithal G.P. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?. Am J Clin Dermatol 2005, 6:357-363.
19. Zachariae H., Kragballe K., Søgaard H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol 1980, 102:407-412.
20. Montaudié H., Sbidian E., Paul C., Maza A., Gallini A., Aractingi S., et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011, 25(Suppl 2):12-18.
21. Tang H., Neuberger J. Review article: methotrexate in gastroenterology-dangerous villain or simply misunderstood?. Aliment Pharmacol Ther 1996, 10:851-858.
22. Barak A.J., Tuma D.J., Beckenhauer H.C. Methotrexate hepatotoxicity. J Am Coll Nutr 1984, 3:93-96.
23. Roenigk H.H., Maibach H.I., Weinstein G.D. Use of methotrexate in psoriasis. Arch Dermatol 1972, 105:363-365.
24. Zachariae H., Heickendorff L., Søgaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001, 144:100-103.
25. Rosenberg P., Urwitz H., Johannesson A., Ros A.M., Lindholm J., Kinnman N., et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007, 46:1111-1118.
26. Dawwas M.F., Aithal G.P. End-stage methotrexate-related chronic liver disease in the United States: interaction of drug, host and environmental factors. Hepatology 2011, 54:134A.
27. Kremer J.M., Lee J.K. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986, 29:822-831.
28. Tishler M., Caspi D., Halperin Z., Baratz M., Moshkowitz M., Yaron M. A prospective analysis of liver biopsies in rheumatoid arthritis patients receiving long term methotrexate therapy. Rheumatol Int 1992, 12:39-41.
29. Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009, 68:1100-1104.
30. Te H.S., Schiano T.D., Kuan S.F., Hanauer S.B., Conjeevaram H.S., Baker A.L. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000, 95:3150-3156.
31. Fournier M.R., Klein J., Minuk G.Y., Bernstein C.N. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol 2010, 105:1620-1626.
32. Tilling L., Townsend S., David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006, 26:55-62.
33. Lindsay K., Gough A. Psoriatic arthritis, methotrexate and the liver-are rheumatologists putting their patients at risk?. Rheumatology (Oxford) 2008, 47:939-941.
34. Laharie D., Seneschal J., Schaeverbeke T., Doutre M.S., Longy-Boursier M., Pellegrin J.L., et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol 2010, 53:1035-1040.
35. Miele L., Vallone S., Cefalo C., La Torre G., Di Stasi C., Vecchio F.M., et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009, 51:778-786.
36. Gisondi P., Targher G., Zoppini G., Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009, 51:758-764.
37. Malatjalian D.A., Ross J.B., Williams C.N., Colwell S.J., Eastwood B.J. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996, 10:369-375.
38. Weinstein G., Roenigk H.H., Maibach H., Cosmides J., Halprin K., Millard M. Psoriasis-liver-methotrexate interactions. Arch Dermatol 1973, 108:36-42.
39. Newman M., Auerbach R., Feiner H., Holzman R.S., Shupack J., Migdal P., et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989, 125:1218-1224.
40. Ashton R.E., Millward-Sadler G.H., White J.E. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982, 79:229-232.
41. Whiting-O'Keefe Q.E., Fye K.H., Sack K.D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991, 90:711-716.
42. Lanse S.B., Arnold G.L., Gowans J.D., Kaplan M.M. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio. Dig Dis Sci 1985, 30:104-109.
43. Reese L.T., Grisham J.W., Aach R.D., Eisen A.Z. Effects of methotrexate on the liver in psoriasis. J Invest Dermatol 1974, 62:597-602.
44. Themido R., Loureiro M., Pecegueiro M., Brandão M., Campos M.C. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol 1992, 72:361-364.
45. Berends M.A., Snoek J., de Jong E.M., van de Kerkhof P.C., van Oijen M.G., van Krieken J.H., et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther 2006, 24:805-811.
46. Robinson J.K., Baughman R.D., Auerbach R., Cimis R.J. Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals. Arch Dermatol 1980, 116:413-415.
47. Arena U., Stasi C., Mannoni A., Benucci M., Maddali-Bongi S., Cammelli D., et al. Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis. Dig Liver Dis 2011, 44:149-153.
48. Dahl M.G., Gregory M.M., Scheuer P.J. Methotrexate hepatotoxicity in psoriasis-comparison of different dose regimens. Br Med J 1972, 1:654-656.
49. Podurgiel B.J., McGill D.B., Ludwig J., Taylor W.F., Muller S.A. Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin Proc 1973, 48:787-792.
50. Boffa M.J., Chalmers R.J., Haboubi N.Y., Shomaf M., Mitchell D.M. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995, 133:774-778.
51. Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand A 1977, 85:511-518.
52. Khan N., Abbas A.M., Whang N., Balart L.A., Bazzano L.A., Kelly T.N. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis 2011, 18:359-367.
53. Fisher M.C., Cronstein B.N. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009, 36:539-545.
54. Mena J.P., Salazar-Páramo M., González-López L., Gámez-Nava J.I., Sandoval- Ramirez L., Sánchez J.D., et al. Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases. Pharmacogenomics J 2011, 11:287-291.
55. Bohanec Grabar P., Logar D., Lestan B., Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 2008, 64:1057-1068.
56. Kooloos W.M., Wessels J.A., van der Straaten T., Allaart C.F., Huizinga T.W., Guchelaar H.J. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 2010, 11:163-175.
57. Ranganathan P., Culverhouse R., Marsh S., Mody A., Scott-Horton T.J., Brasington R., et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008, 35:572-579.
58. Aithal G.P. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol 2011, 7:139-150.
59. Aithal G.P. Dangerous liaisons: drug, host and the environment. J Hepatol 2007, 46:995-998.
60. Freeman-Narrod M. Choline antagonism of methotrexate liver toxicity in the rat. Med Pediatr Oncol 1977, 3:9-14.
61. Chabner B.A., Allegra C.J., Curt G.A., Clendeninn N.J., Baram J., Koizumi S., et al. Polyglutamation of methotrexate. Is methotrexate a prodrug?. J Clin Invest 1985, 76:907-912.
62. Mato J.M., Lu S.C. Homocysteine, the bad thiol. Hepatology 2005, 41:976-979.
63. Basseri S., Austin R.C. ER stress and lipogenesis: a slippery slope toward hepatic steatosis. Dev Cell 2008, 15:795-796.
64. Adinolfi L.E., Ingrosso D., Cesaro G., Cimmino A., D'Antò M., Capasso R., et al. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 2005, 41:995-1003.
65. Oscan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.
66. Ji C., Kaplowitz N. ER stress: can the liver cope?. J Hepatol 2006, 45:321-333.
67. Herron M.D., Hinckley M., Hoffman M.S., Papenfuss J., Hansen C.B., Callis K.P., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005, 141:1527-1534.
68. Mitchell D., Smith A., Rowan B., Warnes T.W., Haboubi N.Y., Lucas S.B., et al. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. Br J Dermatol 1990, 122:1-7.
69. West S.G. Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997, 23:883-915.
70. Younossi Z.M., Stepanova M., Rafiq N., Makhlouf H., Younoszai Z., Agrawal R., et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011, 53:1874-1882.
71. Smith C.H., Barker J.N. Psoriasis and its management. BMJ 2006, 333:380-384.
72. West J., Card T.R. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology 2010, 139:1230-1237.
73. Rousselet M.C., Michalak S., Dupré F., Croué A., Bedossa P., Saint-André J.P., et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005, 41:257-264.
74. Bedossa P., Dargère D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
75. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-1906.
76. Boffa M.J., Smith A., Chalmers R.J., Mitchell D.M., Rowan B., Warnes T.W., et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996, 135:538-544.
77. Zachariae H., Søgaard H., Heickendorff L. Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies-a further 10-year follow-up. Dermatology 1996, 192:343-346.
78. vanDooren-Greebe R.J., Kuijpers A.L., Buijs W.C., Kniest P.H., Corstens F.H., Nagengast F.M., et al. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. Br J Dermatol 1996, 134:481-487.
79. Zachariae H., Aslam H.M., Bjerring P., Søgaard H., Zachariae E., Heickendorff L. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991, 25:50-53.
80. Zachariae H., Søgaard H., Heickendorff L. Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics. Acta Derm Venereol 1989, 69:241-244.
81. Chalmers R.J., Kirby B., Smith A., Burrows P., Little R., Horan M., et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005, 152:444-450.
82. Maurice P.D.L., Maddox A.J., Green C.A., Tatnall F., Schofield J.K., Stott D.J. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005, 152:450-457.
83. Lindsay K., Fraser A.D., Layton A., Goodfield M., Gruss H., Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 2009, 48:569-572.
84. Boffa M.J., Smith A., Chalmers R.J. Comment on: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 2009, 48:1464. [author reply 1465].
85. Guha I.N., Parkes J., Roderick P., Chattopadhyay D., Cross R., Harris S., et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008, 47:455-460.
86. Berends M.A., Snoek J., de Jong E.M., Van Krieken J.H., de Knegt R.J., van Oijen M.G., et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007, 27:639-645.
87. Park S.H., Choe J.Y., Kim S.K. Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine 2010, 77:588-592.
88. Barker J., Horn E.J., Lebwohl M., Warren R.B., Nast A., Rosenberg W., et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011, 25:758-764.
89. Kremer J.M., Alarcón G.S., Lightfoot R.W., Willkens R.F., Furst D.E., Williams H.J., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994, 37:316-328.